Pharmacokinetics
CNL
PK data was available and analyzed for 14 patients and is outlined in Table PK Parameters99,533 ± 52,132Ceramide and Metabolite Concentrations. This is a graphical representation of the mean doses for C6-ceramide and ceramide metabolites over a 24-h period after administration of CNL. Future studies may shed light on the predictive relevance of ceramide metabolites on clinical outcomes